Welcome to our dedicated page for Dariohealth news (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on Dariohealth stock.
DarioHealth Corp. (NASDAQ: DRIO) is a digital health company focused on multi-chronic condition management through a user-centric digital therapeutics platform, and its news flow reflects developments across technology, clinical evidence, commercial traction and corporate strategy. News items frequently describe how Dario’s platform and suite of solutions deliver personalized, dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Recent announcements have highlighted the launch of DarioIQ™, an artificial intelligence layer integrated into the Dario Health app. This AI capability, initially introduced for a cohort of hypertension members in a direct-to-consumer setting, is described as a clinically aligned, conversational layer that integrates behavioral insights, real-time biometric interpretation and personalized guidance while working alongside Dario’s human coaching framework. The company’s news coverage explains how DarioIQ™ is intended to enhance chronic condition management without replacing human-centered guidance.
DarioHealth’s news also emphasizes peer-reviewed clinical and economic evidence. Publications in JMIR Cardio and the Journal of Medical Internet Research (JMIR) have been featured in press releases, detailing studies of data-driven digital nudges for blood pressure management and analyses of healthcare utilization and medical costs among adults with type 2 diabetes using Dario’s platform compared to matched individuals receiving usual care. These articles are presented as supporting evidence for Dario’s ability to impact outcomes and healthcare burden.
Investors and observers following DRIO news will also see updates on employer and health plan adoption, including the signing of new employer clients and expansion of Dario’s commercial pipeline, as well as financing events such as private placements and strategic reviews initiated by the Board of Directors. Together, these news items provide context on how DarioHealth develops its technology, validates its approach through research and pursues growth with payers, employers and partners.
DarioHealth Corp. (Nasdaq: DRIO) announced its financial results for Q4 and the full year 2020, highlighting a transition to a SaaS model and B2B2C digital therapeutics approach. Total revenues rose modestly in Q4 to $2.08 million, a 15.7% increase year-over-year. However, gross profit declined to $549,000, marking a 34.6% drop, while operating losses surged 117% to $9.1 million. The company secured key contracts and successfully raised $70 million through a private placement. Cash reserves stand at approximately $90 million, supporting future growth initiatives.
DarioHealth Corp. (NASDAQ: DRIO) will participate in the Stephens 2021 Best Ideas Conference on March 11, 2021. CEO Erez Raphael and President Rick Anderson will present virtually at 9:00 a.m. ET, with a live webcast available for replay. DarioHealth specializes in digital therapeutics, offering AI-powered solutions for chronic conditions like diabetes and hypertension. The company aims to drive behavioral change through personalized experiences and clinically proven digital tools. For more details, visit dariohealth.com.
DarioHealth Corp. (Nasdaq: DRIO) announced new findings in a clinical study published in JMIR Diabetes, focusing on the impact of digital engagement in managing Type 2 diabetes. The study examined 998 users and revealed that highly engaged users had a 43% decrease in monthly average glucose levels compared to less engaged users. The results emphasize the importance of dynamically personalized engagement over static approaches. DarioHealth aims to integrate behavioral science and AI to enhance user experience and health outcomes, positioning itself as a leader in the digital therapeutics sector.
DarioHealth Corp. (Nasdaq: DRIO) will announce its financial results for Q4 and the full year ended December 31, 2020, on March 9, 2021, at 8:30 am Eastern Time. The conference call will feature leadership including CEO Erez Raphael and CFO Zvi Ben-David. Participants are encouraged to join 10 minutes early. A replay will be available two hours post-call until April 9, 2021. DarioHealth focuses on digital therapeutics, providing evidence-based interventions for those with chronic conditions, including diabetes, through its MyDario™ app.
DarioHealth Corp. (Nasdaq: DRIO) has announced its participation in the Cowen 41st Annual Health Care Conference, set to take place virtually from March 1-4, 2021. CEO Erez Raphael and President Rick Anderson will present on March 1st at 11:00 a.m. ET. DarioHealth is a leader in digital therapeutics, offering AI-powered solutions aimed at managing chronic conditions like diabetes and hypertension. The company emphasizes personalized experiences and clinically proven tools to foster health improvements.
DarioHealth Corp. (Nasdaq: DRIO) is set to participate in the 10th Annual SVB Leerink Global Healthcare Conference from February 24 to 26, 2021. CEO Erez Raphael will host investor meetings during the event, emphasizing Dario's role in the digital therapeutics market. The company is known for its AI-powered solutions aimed at chronic condition management, particularly in diabetes and hypertension. DarioHealth is expanding its reach across various health conditions and geographic markets, focusing on personalized experiences and evidence-based interventions.
DarioHealth Corp. (Nasdaq: DRIO) has announced its acquisition of Upright Technologies Ltd., a digital musculoskeletal (MSK) company, in a stock transaction valued at $31 million. This move expands Dario's digital therapeutic platform, which already serves around 150,000 users, by adding a clinically validated MSK solution that aligns with its focus on chronic conditions. Concurrently, Dario secured $70 million through a private placement to enhance its cash reserves, aiming to fortify its market position. The transaction is expected to close on or about February 7, 2021.
Summary not available.
DarioHealth Corp. (Nasdaq: DRIO) announced the addition of Dr. Marilyn Ritholz and Dr. David Horwitz to its Scientific Advisory Board, enhancing its digital therapeutics platform aimed at chronic condition management. The SAB's mission includes leveraging their expertise to improve clinical offerings and market penetration. Dr. Ritholz specializes in diabetes and behavioral health, while Dr. Horwitz has extensive experience in clinical affairs at major diabetes organizations. This strategic move is expected to further advance Dario's AI-driven health solutions, focused on personalized care.
DarioHealth Corp. (NASDAQ: DRIO) has appointed Claudia Rimerman Kraut as Vice President of Broker and Consultant Partnerships, a new role aimed at enhancing their sales strategy. Ms. Kraut brings extensive experience from her previous role at Omada Health, where she built strong partnerships. Rick Anderson, President of North America, expressed confidence that her expertise will accelerate growth opportunities in 2021 and beyond. The company emphasizes its innovative digital therapeutic solutions aimed at chronic condition management, further strengthening its market position.